Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APX 343A

Next Previous
Drug Profile

APX 343A

Alternative Names: APX-343A

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AptaBio Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Sep 2025 Aptabio Therapeutics plans a phase I trial for (Late-stage disease, Monotherapy, Combination therapy) in South Korea (PO), in October 2025 (NCT07123415)
  • 29 Jun 2025 APX 343A receives Orphan Drug status for Solid tumours in USA
  • 23 Jun 2025 The MFDS approves IND application for APX 343A in Solid tumours in South Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top